We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The price of priority review: $67.5 million.
- Authors
Senior, Melanie
- Abstract
The article reports on the $67.5 million price for the U.S.Food and Drug Administration's (FDA) priority review voucher (PRV). San Rafael, California-based BioMarin Pharmaceutical Inc. is the first company to publicly sell a PRV, which provides a four-month shortcut through the U.S. drug approval pathway, in August 2014. Tarrytown, New York-based Regeneron Pharmaceuticals Inc. and partner Paris-based Sanofi-Aventis SA purchased the voucher for their biologic to treat hypercholesterolemia.
- Subjects
UNITED States. Food &; Drug Administration; DRUG approval; BIOMARIN Pharmaceutical Inc.; REGENERON Pharmaceuticals Inc.; SANOFI-Aventis SA; HYPERCHOLESTEREMIA treatment
- Publication
Nature Biotechnology, 2014, Vol 32, Issue 10, p973
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt1014-973